Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Hansa Biopharma is a Swedish commercial-stage biopharmaceutical company focused on rare immunological conditions. Its lead product, Idefirix (imlifidase), is an IgG-cleaving enzyme approved in Europe for desensitization in kidney transplant patients with high antibody levels, addressing a market of approximately 3,000-4,000 highly sensitized patients annually in Europe. The company is pursuing US FDA approval and expanding into antibody-mediated rejection and other transplant indications.
Hansa generates revenue by selling Idefirix to European transplant centers at premium pricing (estimated €50,000-80,000 per treatment course) for highly sensitized kidney transplant patients who would otherwise face years on dialysis. The drug's unique mechanism—rapidly cleaving pathogenic IgG antibodies—provides a first-in-class solution with limited competition. Pricing power stems from high unmet need, life-changing clinical benefit, and cost-effectiveness versus lifetime dialysis (€50,000+ annually). Commercial expansion depends on securing US FDA approval (currently under review), penetrating the larger US market (estimated 6,000-8,000 patients annually), and expanding into antibody-mediated rejection treatment.
US FDA approval timeline and outcome for Idefirix in kidney transplant desensitization (pivotal catalyst)
Quarterly European commercial uptake metrics and revenue trajectory
Clinical trial readouts for antibody-mediated rejection indication and other pipeline programs
Cash runway updates and financing needs given negative operating cash flow of $70M annually
Reimbursement decisions in key European markets (Germany, France, UK) affecting pricing and access
Regulatory risk: US FDA approval uncertainty for Idefirix, with potential for clinical hold, additional trial requirements, or rejection impacting the primary growth catalyst and US market access worth potentially $300M+ annually
Reimbursement risk: European payers may restrict coverage or negotiate lower pricing, compressing margins in the company's only current commercial market
Single-product dependency: Over 90% of revenue concentrated in one product for one indication creates binary risk if safety issues, competitive threats, or market access problems emerge
Alternative desensitization approaches including plasmapheresis, IVIG, and emerging antibody-targeting therapies could limit market penetration despite Idefirix's differentiated mechanism
Large pharmaceutical companies developing competing IgG-modulating therapies with greater resources for clinical development and commercialization
Severe cash burn: $70M annual negative operating cash flow with current ratio of 1.94 suggests 12-18 months of runway, requiring dilutive equity financing or partnerships
Negative equity position: Debt/Equity of -11.10 and negative book value indicate accumulated losses exceeding assets, typical for pre-profitable biotech but limiting financial flexibility
No debt capacity: Negative equity and lack of profitability eliminate traditional debt financing options, forcing reliance on equity markets or strategic partnerships during potential market downturns
low - Kidney transplantation is a medically necessary procedure driven by clinical need rather than discretionary spending. Highly sensitized patients face life-threatening conditions requiring dialysis, making treatment demand relatively inelastic to economic cycles. However, hospital budget constraints during recessions could modestly delay elective transplant procedures.
Rising interest rates negatively impact valuation multiples for pre-profitable biotech companies as future cash flows are discounted more heavily. Higher rates also increase the cost of capital for potential future financing rounds needed to fund operations until profitability. The company's negative $70M annual cash burn makes it sensitive to financing conditions, though rates have minimal direct operational impact on the business model.
minimal - The business model does not rely on consumer or commercial credit. Revenue comes from hospital/healthcare system purchases with established payment mechanisms. Primary financial risk is equity financing availability rather than credit market conditions.
growth - Attracts speculative biotech investors focused on binary FDA approval catalysts and rare disease commercial opportunities. The stock appeals to investors willing to accept high risk for potential multi-bagger returns if US approval succeeds and commercial execution delivers. Not suitable for value or income investors given negative profitability, no dividends, and high cash burn requiring future dilution.
high - Small-cap biotech with $200M market cap, binary regulatory catalysts, and single-product revenue concentration creates extreme volatility. Stock likely experiences 20-40% moves on clinical/regulatory news. Low trading liquidity in US OTC markets amplifies price swings.